Abstract:e21505 Background: Acral and mucosal melanoma are rare in Caucasians but have higher incidence in Asians and have poor prognosis. However, it has been reported that monotherapy seems to have limited efficacy in these population. Therefore, new treatments especially novel combination therapy are needed to further improve the outcome for these two subtypes. Here, we present the efficacy and safety of PEMBRO combined with TMZ in previously untreated pts with advanced acral and mucosal melanoma in China. Methods: The records of pts in Fudan University Shanghai Cancer Center with metastatic and unresectable acral and mucosal melanoma firstly treated with PEMBRO plus TMZ, PEMBRO alone or TMZ/DTIC based chemotherapy (CHEMO) were reviewed. Data regarding to best objective response rate (ORR), progression free survival (PFS) and toxicities were estimated. Response to treatment was assessed based on direct review of scan images and radiology reports according to the RECIST 1.1 criteria. Safety and tolerability were assessed per NCI-CTCAE v 4.0. Results: From May 2018 to February 2020, 49 pts were identified, including 28 (57.1%) with acral melanoma, 21 (42.9%) with mucosal melanoma. 32 (65.3%) pts had prior received adjuvant treatment, of which most (15, 30.6%) were interferon-α (IFN-α) or interleukin-2 (IL-2). Among these pts, PEMBRO alone was received by 18 (36.7%) pts with standard dosing of 2 mg/kg every 3 weeks. 20 (40.8%) pts received CHEMO at standard recommended dosing schedule, of which TMZ was given at 200 mg/m 2 orally days 1–5, every 4 weeks. PEMBRO plus TMZ was given to 11 (22.4%) pts with the same dosing of each treatment alone. The ORR of PEMBRO plus TMZ (6/11, 54.5%) was significantly higher than PEMBRO alone (2/18, 11.1%; p = 0.011) or CHEMO(1/20, 5.0%; p = 0.002), however, the difference of ORR between PEMBRO alone and CHEMO was not statistically significant ( p = 0.485). The disease control rate of the three groups were 81.8%, 72.2% and 70.0% respectively (not significant). The median PFS of PEMBRO plus TMZ in the front-line therapy was 9.8 months (95% CI, 3.2 -16.4), as compared with 6.2 months (95% CI, 1.8 - 10.3) in PEMBRO alone and 4.2 months (95% CI, 2.8 - 5.6) in CHEMO ( p = 0.258). Grade 3 treatment-related adverse events (TRAEs) occurred in one acral melanoma patient (rash) in PEMBRO plus TMZ and two pts in CHEMO (one thrombocytopenia and one anemia, both were mucosal melanoma). No grade 3 TRAEs was reported in PEMBRO alone. There were no significant differences in grade 1/2 toxicity, with the common TRAEs including nausea, vomiting, fatigue, elevated transaminase and leukocytopenia. Conclusions: These results suggest that the combination of PEMBRO plus TMZ as first line therapy for advanced acral and mucosal melanoma could potentially be an effective strategy to enhance antitumor activity with a manageable toxicity profile. Need to be further evaluated in a large prospective study.

Durable Response of the Triple Combination of Temozolomide, Sorafenib, and Bevacizumab to Treat Refractory Stage Iv Acral Melanoma.

Durable Response of the Triple Combination of Temozolomide, Sorafenib, and Bevacizumab As Second-Line Therapy for Patients with Stage Iv Acral Melanoma

Salvage Therapy for Metastatic Acral or Mucosal Melanoma: Efficacy and Safety Analysis of Nab-Paclitaxel/carboplatin Combined with Bevacizumab in C-Kit/braf Wild-Type Pts.

Camrelizumab Plus Apatinib and Temozolomide As First-Line Therapy for Advanced Acral Melanoma: 2-Year Survival Results from CAP 03.

Camrelizumab Plus Apatinib and Temozolomide As First-Line Treatment in Patients with Advanced Acral Melanoma the CAP 03 Phase 2 Nonrandomized Clinical Trial

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma

Combination of pembrolizumab (PEMBRO) plus temozolomide (TMZ) therapy in Chinese patients (pts) with advanced acral and mucosal melanoma.

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure

Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma.

Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.

Efficacy and Safety of Combined Anti-Angiogenic Chemoradiotherapy with PD-1 Monoclonal Antibody in Advanced Melanoma: A Retrospective Study.

A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).

Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma

Neoadjuvant Oncolytic Virus Orienx010 and Toripalimab in Resectable Acral Melanoma: a Phase Ib Trial

BRAF Inhibitors: Efficacious and Tolerable in BRAF-mutant Acral and Mucosal Melanoma.

Efficacy and Tolerability of Vemurafenib in BRAF-mutant Acral and Mucosal Melanoma.

Preoperative Treatment for Marginally Resectable Metastatic Melanoma: A Single Center Experience in China.

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives